Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma: Study Protocol for An International Multicenter Prospective Cohort Study (ENCRAM 2302)

NCT06283927 is registered in ClinicalTrials.gov with Jasper Gerritsen as lead sponsor.

NCT NCT06283927
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06283927 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma: Study Protocol for An International Multicenter Prospective Cohort Study (ENCRAM 2302)
Lead sponsor
Jasper Gerritsen
Phase
Observational
Overall status
Recruiting
Start date
January 1, 2023
Completion date
January 1, 2028
Enrollment
464 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

astrocytoma of brain, astrocytoma, malignant, glioblastoma, glioblastoma multiforme, glioblastoma multiforme of brain, glioblastoma multiforme, adult, glioblastoma, idh-wildtype, recurrent glioblastoma